Literature DB >> 6305607

Evaluation of antisecretory drug therapy of Zollinger-Ellison syndrome (ZES) using 24-hour pH monitoring.

T Vallot, M Mignon, R Mazure, S Bonfils.   

Abstract

Clinical and endoscopic findings were compared with 24-hr pH profiles in 8 patients with Zollinger-Ellison syndrome (ZES), who were being treated, during consecutive periods, with doses of cimetidine or ranitidine. There was a positive correlation between the effect on gastric pH and the outcome of treatment, with ranitidine proving to be more effective. The reduction of gastric acidity was correlated with ranitidine plasma levels. In the medical management of ZES patients, the 24-hr pH profile appears to be a measurement which is of value in the choice of appropriate drug regimes and which promises to increase our understanding of treatment failure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6305607     DOI: 10.1007/bf01299916

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  13 in total

1.  Testing antisecretory drugs in Zollinger-Ellison syndrome: problems and limits in pharmacological studies.

Authors:  S Bonfils
Journal:  Dig Dis Sci       Date:  1982-04       Impact factor: 3.199

2.  Management of Zollinger-Ellison syndrome.

Authors:  S Bonfils; M Mignon; J H Landor
Journal:  N Engl J Med       Date:  1980-10-16       Impact factor: 91.245

3.  [Ranitidine effects on 24-hour intragastric pH in normal individuals. Interest of continuous monitoring for selection of an optimal therapeutic regimen (author's transl)].

Authors:  J P Galmiche; T Vallot; S Mayeur; D Arsène; P Ducrotte; P Duvaldestin; M Mignon
Journal:  Gastroenterol Clin Biol       Date:  1982-04

4.  Reduction of twenty-four-hour gastric acidity with combination drug therapy in patients with duodenal ulcer.

Authors:  W L Peterson; C Barnett; M Feldman; C T Richardson
Journal:  Gastroenterology       Date:  1979-11       Impact factor: 22.682

5.  Effect of isopropamide on response to oral cimetidine in patients with Zollinger--Ellison syndrome.

Authors:  D M McCarthy; P E Hyman
Journal:  Dig Dis Sci       Date:  1982-04       Impact factor: 3.199

6.  Complete inhibition of food-stimulated gastric acid secretion by combined application of pirenzepine and ranitidine.

Authors:  W Londong; V Londong; C Ruthe; P Weizert
Journal:  Gut       Date:  1981-07       Impact factor: 23.059

7.  Report on the United States experience with cimetidine in Zollinger-Ellision syndrome and other hypersecretory states.

Authors:  D M McCarthy
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

8.  Interest of a combined antisecretory treatment, cimetidine and pirenzepin, in the management of severe forms of Zollinger-Ellison syndrome.

Authors:  M Mignon; T Vallot; J P Galmiche; J L Dupas; S Bonfils
Journal:  Digestion       Date:  1980       Impact factor: 3.216

9.  Comparison of the effects of ranitidine, cimetidine and placebo on the 24 hour intragastric acidity and nocturnal acid secretion in patients with duodenal ulcer.

Authors:  R P Walt; P J Male; J Rawlings; R H Hunt; G J Milton-Thompson; J J Misiewicz
Journal:  Gut       Date:  1981-01       Impact factor: 23.059

10.  Cimetidine treatment of acute and chronic Zollinger-Ellison syndrome.

Authors:  S Bonfils; M Mignon; J Gratton
Journal:  World J Surg       Date:  1979-09-20       Impact factor: 3.352

View more
  8 in total

1.  Famotidine and ranitidine control of 24 h intragastric acidity after single bedtime administration: a study using continuous pH monitoring.

Authors:  V Savarino; G S Mela; P Scalabrini; E Di Timoteo; M R Magnolia; G Percario; G Celle
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

2.  Current approach to the management of tumoral process in patients with gastrinoma.

Authors:  M Mignon; P Ruszniewski; S Haffar; D Rigaud; E Rene; S Bonfils
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

3.  New somatostatin molecule for management of endocrine tumours.

Authors:  S Bonfils
Journal:  Gut       Date:  1985-05       Impact factor: 23.059

Review 4.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

5.  Basis for failure of cimetidine in patients with Zollinger-Ellison syndrome.

Authors:  R T Jensen
Journal:  Dig Dis Sci       Date:  1984-04       Impact factor: 3.199

Review 6.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

7.  Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists.

Authors:  J C Delchier; J C Soule; M Mignon; D Goldfain; A Cortot; B Travers; J P Isal; J P Bader
Journal:  Dig Dis Sci       Date:  1986-07       Impact factor: 3.199

Review 8.  Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome.

Authors:  D C Metz; J R Pisegna; V A Fishbeyn; R V Benya; R T Jensen
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.